MAIN MENU

BACK

BACK

  • Home

  • About
  • News & Events
  • Careers
  • Countries
  • Contact Us
  • Volunteer
  • PAREXEL Academy
  • Partners
  • Client Login
Explore PAREXEL
  • JourneyGO
  • SolutionsGO
  • ExperienceGO
  • Outsourcing ModelsGO
  • Planning
  • Phase I
  • Phase IIa
  • Phase II-III
  • Phase IIIb-IV
  • Post Launch
  • PAREXEL® Biotech
  • Clinical Research
    • Early Phase Services
      • Dedicated Therapeutic Expertise
        • Early Phase and Late Phase integrated study management
      • Patient Populations
      • Strategic Locations
        • Berlin
          • Virtual Tour
        • London
        • Baltimore
          • Facility
          • Virtual Tour
        • Los Angeles
          • Virtual Tour
      • Phase 1, First in Human
        • Ethnobridging for Accelerated Global Drug Development
      • Phase IIa, Proof of Concept
      • Early Product Development
      • Ethnobridging
      • Clinical PK/PD and Pharmacometrics Services
        • Case Study: Safety/Pharmacovigilance #1
        • Case Study: Safety/Pharmacovigilance #2
      • Bioanalytical and Biomarkers
      • Bioequivalence Studies
      • Volunteer to Participate
    • Phase II-III Services
      • Phase III
        • Case Study: Chronic Renal Failure
        • Case Study: Expanded Access Program
        • Case Study: Accelerating development in global COPD trials
      • Feasibility and Enrollment
        • Patient Recruitment
          • Case Study: Pediatric Migraine Patient Recruitment
        • Country and Site Selection
        • Alliance Site Strategy
        • Protocol Optimization
    • Phase IIIb-IV
    • ForeSite™ Clinical Trial Methodology
      • Study Design
      • Study Start-Up
      • Study Execution
    • Global Data Operations
      • Clinical Data Management
      • Biostatistics Services
      • Clinical MetaData Repository (MDR)
    • Medical Writing Solutions
    • Quantitative Clinical Development Services
    • Clinical Trial Supplies & Logistics
      • Global Reach
      • Clinical Trial Supplies
      • Ancillary Supplies
      • Laboratory Logistics and Biological Sample Lifecycle Management Services
      • Randomization and Trial Supply Management
      • Cold Chain Logistics
      • Clinical Trial Supply Chain - Active Tracking
    • Customer Care Services
    • Genomic Medicine Services
    • Clinical Adjudication Services
  • Informatics
    • Clinical Technology
      • Clinical Trial Management System (CTMS)
      • Electronic Data Capture
      • MyTrials® Analytics
      • Perceptive® Cloud
      • Data-Driven Monitoring
    • Patient Technology
      • Randomization and Trial Supply Management
        • Clinical Trial Supplies & Logistics
        • Clinical Trial Supply Chain - Active Tracking
        • ClinPhone RTSM Mobile App
      • Medical Imaging
        • Therapeutic Expertise
          • Oncology Imaging Expertise
            • Criteria Experience
              • 1996 NCI-WG CLL
              • IWCLL 2008
                • Key Topics: IWCLL 2008
                  • Definitions
                  • Usable Criteria to Evaluate
                  • Target Sites of Disease
                  • Non-Target Sites of Disease
                  • Organomegaly
                  • New Lesions
                  • B symptoms
                  • Blood Counts
                  • Bone Marrow
                  • Transformation
                  • Role of Imaging in CLL Clinical Trials
                  • Clinical Data Assessments
              • 1999 IWG-NHL
              • 2007 IWG-NHL
                • Key Topics: 2007 IWG-NHL Assessment Criteria
                  • Definitions
                  • Usable Criteria to Evaluate
                  • Target Sites of Disease
                  • Non-Target Sites of Disease
                  • Organomegaly
                  • New Lesions
                  • Bone Marrow
                  • Other Laboratory Values and Symptoms
                  • Incorporation of FDG-PET
                  • Defining Normal, Abnormal and Measurable
                  • Problem with CRu
              • RECIST
          • Neurology Imaging Expertise
          • Musculoskeletal (MSK) Imaging Expertise
          • Women's Health Imaging Expertise
          • Dermatology Imaging Expertise
          • Gastroenterology Imaging Expertise
          • Ophthalmology Imaging Expertise
          • Volumetric Imaging Expertise
          • Cardiovascular Imaging Expertise
        • Imaging Services
        • Scientific Advisors
        • Consultation
        • Advanced Medical Imaging
          • Cloud-Based Solutions for Sites
      • Patient Sensors
      • Electronic Clinical Outcome Assessments (eCOA)
        • ePRO (electronic Patient Reported Outcomes)
        • Clinical Outcome Assessments Consulting
    • Regulatory Technology
      • Regulatory Information Management
        • LIQUENT InSight®
        • Regulatory Cloud
        • Regulatory Outsourcing Services
    • Clinical Trial Supplies & Logistics
    • Asset Transfer Services
    • PAREXEL's Education Services
      • IMPACT® CTMS Training
      • LIQUENT InSight® Training
        • Training Resources
      • DataLabs® EDC Training
      • Perceptive MyTrials® Training
      • Data-Driven Monitoring Training
      • Certification Programs
      • Training Services
    • Customer Care Services
  • Regulatory
    • Regulatory Strategy & Development Planning
    • Regulatory GMP Compliance
      • Q&A about GCP
      • Strategic Compliance: Data Integrity
    • Regulatory Partnerships
    • Clinical Trial Regulatory Services
    • China Advisory Services
    • IDMP Solutions
      • IDMP Readiness Assessment
      • IDMP Task Force Updates
        • November 2015 Task Force Meeting
  • Access
    • Real World Evidence
      • Late Phase Clinical Operations
        • Late Phase Interventional Trials
        • Observational Research
        • Epidemiology
        • Expanded Access Programs
        • Clinical Outcome Assessment (COA)
          • Case Study: Health Economics
          • Outcomes Research
      • Real World Data Services
    • Drug Safety Services
      • Risk Management / REMS
    • Market Access Consulting
      • Commercial Decision Pathways
      • Evidence Generation
        • Evidence Review and Meta-Analysis
          • Evidence Review Options
          • Evidence Review Resources
        • Health Economic Modeling
        • Global and AMCP Value Dossiers
        • Manuscripts and Posters
        • Data Analytics
        • Strategic Communications
      • Access Realization
        • Pricing, Reimbursement and Market Access Expertise
        • List of Services: Pricing, Reimbursement and Market Access
    • Medical Communications
      • Communication Strategy
      • Publications Planning and Scientific Content
      • Expert Identification and Engagement
      • Global Study Engagement
      • Branding and Creative Strategy
      • Digital Media and Video Solutions
      • Live and Virtual Events
      • Payer Communication
      • Editorial and Production
    • Outsourced Field-Based Medical Teams
  • Therapeutic Expertise
    • Oncology
    • Cardiovascular & Metabolic Diseases
    • Central Nervous System (CNS) Disorders
    • Infectious Disease
    • Respiratory Capabilities
    • Rheumatology & Immunology Capabilities
    • Rare Diseases
  • Patient Innovation Center
  • Industry Expertise
    • Pharmaceuticals
      • Biosimilar Consulting
    • Medical Devices
    • Biologics
    • Biosimilars
      • Biosimilar Video
  • Regulatory Expertise
  • Market Access Expertise
  • Global Presence
    • North America
    • South America
    • Europe
    • Asia
    • Middle East & Africa
    • Emerging Markets
  • Digital Transformation
  • Strategic Partnerships
  • ExecuPharm Functional Service Solutions
  • About
  • News & Events
  • Careers
  • Countries
  • Contact Us
  • Volunteer
  • PAREXEL Academy
  • Partners
  • Client Login
  • Home
  • Journey
    • Planning
    • Phase I
    • Phase IIa
    • Phase II-III
    • Phase IIIb-IV
    • Post Launch
  • Solutions
    • PAREXEL® Biotech
    • Clinical Research
      • Early Phase Services
      • Phase II-III Services
      • Phase IIIb-IV
      • ForeSite™ Clinical Trial Methodology
      • Global Data Operations
      • Medical Writing Solutions
      • Quantitative Clinical Development Services
      • Clinical Trial Supplies & Logistics
      • Customer Care Services
      • Genomic Medicine Services
      • Clinical Adjudication Services
    • Informatics
      • Clinical Technology
      • Patient Technology
      • Regulatory Technology
      • Clinical Trial Supplies & Logistics
      • Asset Transfer Services
      • PAREXEL's Education Services
      • Customer Care Services
    • Regulatory
      • Regulatory Strategy & Development Planning
      • Regulatory GMP Compliance
      • Regulatory Partnerships
      • Clinical Trial Regulatory Services
      • China Advisory Services
      • IDMP Solutions
    • Access
      • Real World Evidence
      • Drug Safety Services
      • Market Access Consulting
      • Medical Communications
      • Outsourced Field-Based Medical Teams
  • Experience
    • Therapeutic Expertise
      • Oncology
      • Cardiovascular & Metabolic Diseases
      • Central Nervous System (CNS) Disorders
      • Infectious Disease
      • Respiratory Capabilities
      • Rheumatology & Immunology Capabilities
      • Rare Diseases
    • Patient Innovation Center
    • Industry Expertise
      • Pharmaceuticals
      • Medical Devices
      • Biologics
      • Biosimilars
    • Regulatory Expertise
    • Market Access Expertise
    • Global Presence
      • North America
      • South America
      • Europe
      • Asia
      • Middle East & Africa
      • Emerging Markets
    • Digital Transformation
  • Outsourcing Models
    • Strategic Partnerships
    • ExecuPharm Functional Service Solutions
  • Company
    • Management Team
      • Jamie Macdonald
      • Peyton Howell
      • Greg Rush
      • Michael Crowley
      • Michele Fournier
      • Sy Pretorius, M.D.
      • Gadi Saarony
    • News & Events
      • Press Releases
      • Events
      • Webinars
      • 12th Annual Partnerships in Clinical Trials Congress
      • Archived PAREXEL in the News
    • Find an Office
    • Careers
      • Careers at PAREXEL®
      • CEO Message
      • Find Your Path - Opportunities
      • University Graduates – Opportunities for students
    • Volunteer
      • About Us
      • Locations Worldwide
      • About Clinical Trials
      • Why Participate?
      • FAQs
      • Glossary
    • Sustainability
      • Consumption Trend Analysis
    • Code of Conduct
    • eClinical Innovation
    • Purchasing
      • Purchase Order Terms and Conditions
      • Bedingungen für den Kaufauftrag
      • Vigente desde el
      • PO Terms - Japanese
      • PO Terms - Chinese 'S'
      • PO Terms - Chinese 'T'
      • Ordem de Compra Termos e Condições
    • Contact Us
      • Thank You
    • Partners
      • Service Partners
      • Training Partners
      • Technology Partners
      • Referral Partners
      • Accredited Partner Program
    • PAREXEL Reports U.K. Gender Pay Data
    • Tax Strategy
    • Brexit Statement
  • Perceptive®
  • User Group Meeting
    • IMPACT CTMS User Group Meeting Details and Agendas
    • IMPACT CTMS User Group Meeting Justification Letter
    • Meeting Registration and Hotel Details
    • Benefits for attending the IMPACT CTMS User Group Meeting
    • Registration Rates
    • Hotel Rates
  • Horizons
    • Agenda
    • Venue/Location
    • FAQs
    • Speakers
  • RWE Symposia
    • About
    • Locations
    • FAQs
    • Agenda
  • Graduate | PAREXEL
    • Culture at PAREXEL
    • Former Trainees at PAREXEL
      • Career Trainee Meghan
      • Career Trainee Sam
    • Great Place to Work
    • PAREXEL Overview
    • Clinical Trainee Program Belgium
    • Clinical Trainee Program Japan
    • Graduate Scheme India
    • Clinical Research Awards
    • Graduate Scheme UK
  • parexel-insights
    • Precision Medicine’s Next Hurdle: Quality Management of Human Samples
    • Mergers & Acquisitions: Where’s the Real Finish Line?
    • Navigating Regulatory Submissions
    • Increasing Study Predictability
    • When It Comes to CTMS One Size Does Not Fit All
    • This Disease Will Not Win the Fight
    • WHAT CAN WE LEARN FROM IMMUNO-ONCOLOGY CLINICAL TRIALS?
    • A Biosimilar Milestone with Implications
    • Designing Trials Payers Can Trust
    • Recognizing Uncle David
    • RIM & IDMP Synergies
      • PAREXEL's Connected Journey™ of Data-Driven Services
    • High Performance Workplace Practices That Attract and Retain Millennials
    • Utilizing Secondary Healthcare Data Assets
    • Working Towards a Glimpse of a Cure
    • Clarifying the Criteria that Better Capture Antitumor Activity of Immune Therapeutics
    • Josh Schultz, Corp. VP Talks About PAREXEL Access
    • 'Now is the time to include Japan' says PAREXEL
    • Shogo Nakamori Discusses Trends in Drug Development in Japan
    • Dragons - the Guardians of Disease
    • New Approaches to Data Management in Clinical Trials
    • 30 Years Later: Lessons from Living in a Pandemic
    • Shogo Nakamori Discusses Joint Program for Clinical Research
    • Want Your Business to Thrive? Focus on Developing Your People
    • 3 Principles for a Sound Clinical and Regulatory Document Strategy for Small Biopharmaceuticals
    • Imaging Endpoint Selection For Biosimilar Development
    • CONSIDERATIONS IN BIOSIMILARS DEVELOPMENT– A US FDA PERSPECTIVE
    • Accelerated Pathways and Stock Prices
    • Leveraging the Cloud to Accelerate Time to Treatment
    • Developing Drugs in the New Era of Personalized Medicines
    • Clinical Trial Feasibility & Patient Enrollment: Differentiation Through Innovation
    • Interview with PAREXEL’s Aida Sabo, About Challenges & Successes in Diversity & Inclusion
    • Protocol Optimization
    • Why RTSM & IRT stand for Speed, Simplicity & Service
    • The Emerging Role of Wearable Devices For Real-World Data Collection
    • Shogo Nakamori Discusses Japan & Multi-national Trials
    • Demonstrating Value and Managing Risk Throughout Development
    • Grateful for Advancements in Medicine
    • Adaptive Trials: Complex But Advantageous
    • Quantitative Modeling For Clinical Trials
    • The Human Touch: Aligning Reward Systems with Company Strategy and Meaningful Work
    • Involved & Engaged: The Last Mile of Business Performance
    • Orphan Drug Pricing in Europe
    • Generating Evidence to Drive Patient Access
    • World Cancer Day: Breakthroughs and Challenges for Precision Medicine
    • Genomic Medicine, Data Modeling and Clinical Trials
    • PAREXEL’s Training Approach and the Importance of Training a Global Workforce
    • Rooting for Team Jessie
    • On Demand Webinar - The Power of Foresight: Improving Drug Development Performance through Optimized Protocol Design
    • "Yes, I Can!"
    • How to Simplify Site Tasks and Help Ensure Dispensing Accuracy
    • PAREXEL's Connected Journey™ of Data-Driven Services
    • Something Good Always Comes From Something Bad
    • Life is Short and Love is Eternal
    • Clinical Development of Next Generation Biologics
    • Medical Writing for Submission to Asia-Pacific Regulatory Authorities
    • The Collaborative Advantage of Biopharma Companies and Global Service Providers
    • Focused on the Finish Line
    • Three Skills Developers Will Need to Thrive in the New Era of Genomic Medicine
    • Surveillance or Surgery?
    • Accelerated Pathways & Commercial Consequences Forum & Findings
    • Using Analytics to Optimize The Clinical Development Process
    • Beyond Diversity: What Happens When You Define a Culture of Inclusion
    • The Complete Journey: Improving Clinical Trials Using Modern Technology
    • If You Never Stop Learning, You Can Never Stop Earning
    • Best Practices to Improve the IRT Site User Experience
    • A People Strategy Attracts the Best Talent
    • Navigating Regulatory Complexities Of Biosimilar Development
    • Contracting - A Key Component Of A Strong Vendor Relationship
    • Improving Site Experience with Risk-Based Monitoring
    • Accelerated Pathways: Global Opportunities & Challenges for Innovators
    • How do eClincal solutions Increase Clinical Trial Efficiency?
    • Immuno-Oncology: Past, Present and Future
    • Albert Liou Discusses the Drug Development Landscape in Korea
    • Training Compliance is an Increasingly Complex Journey
    • Successfully Integrating Electronic Health Record and Electronic Data Collection Data
    • PAREXEL Celebrates Women In STEM
    • The Next Generation of Talent Management: Opportunities For Diversity
    • The Clinical, Regulatory and Commercial Implications of Rapid Approval
    • How to Maximize Potential and Sidestep Pitfalls of MAPs
    • Running with a Purpose
    • The Evolution of Drug Development & Market Access via Connected Data-driven Solutions
    • Biosimilar mAbs – a unique and distinct market (for the time being…?)
    • World Cancer Day: Reflecting on Progress and Hope for Patients
    • Wearables Shaping the Future of Clinical Trials
    • Progress in Pursuit of a Cure - World AIDS Day 2017
    • Optimizing the clinical development process with Social, Mobile, Analytics, and Cloud (SMAC)
    • Three Keys To Mitigating Risk In Adaptive Trials
    • Get Into Pole Position with Modern IRT Services
    • Overcoming Data Capture and Management Challenges
    • How Protocol Optimization Improves Clinical Trial Outcomes
    • How Performance Reviews Support High-Performance Talent
    • Diversity and Inclusion: This Is How the Best Global Companies Learn, Plan, and Measure Success
    • The Impact of the Digital Human Resources Organization on People - Part 1
    • Data Management Roles, Process and Technologies in Risk Based Study Execution
    • Recorded Webinar: Getting to Approval Faster Through Technology Innovation
    • Attitude is Everything
    • What You Need To Know About Biosimilars Development
    • Why Strategy is Not Enough: Building the Bridge From Strategy to Results Requires Organizational Excellence
    • When the Doctor Becomes the Patient
    • Your clinical trial supply may be at risk – Brexit and the impact on IMP distribution
    • Dr. Sy Pretorius, Chief Scientific Officer Talks About Adaptive Design Trials
    • Drew Garty Discusses Data Driven Monitoring
    • Dream or Reality- Improving Patient Safety & Reducing Costs?
    • Innovation in the Pharmaceutical Industry: A Change Toward Personalized Medicine
    • Key Considerations In Biologics Clinical Development
    • Albert Siu, PhD, Explains How PAREXEL Academy Benefits Clients
    • How to Know You’re Keeping Your (Clinical Trial Supplies) Cool
    • Anything is Possible
    • Effective Late Stage Pathways For Biosimilar Products
    • The Life of a Human Biological Sample: A Look Inside and How to Maintain Its Integrity
    • You’re Hot Then You’re Cold -Temperature Management & RTSM Integration
    • Clinical Trial Support Query - Who Ya Gonna Call?
    • Aligning on Patient Outcomes – How Market Dynamics Can Facilitate RWD (Real World Data) Solutions in Research
    • Active Tracking Is Out To Reduce Sites’ Workload
    • Ubavka DeNoble Talks About PAREXEL's BioPharm Unit
    • The Journey Continues – I Got This
    • So, My Fitbit is Clinical Trial Grade Right?
    • Latin America’s Role in Clinical Studies
    • Trends in Translational Development
    • Effective use of Value to Achieve Optimal Market Access
    • Three Ways to Mitigate the Risk of Late-stage Failure in CNS Drug Development
    • HOW TO EFFECTIVELY DEVELOP CLINICAL DOCUMENTS IN THE EU/US AND CHINA NDA DOSSIER
    • The Art and Science of Productive FDA Meetings
    • Regulatory Strategy In Emerging Markets
    • Exploring Our Partnership with CHA Medical Group
    • PAREXEL Introduces Jamie Macdonald as Chief Executive Officer
    • Understanding different stakeholder requirements throughout commercialization
    • Development considerations: Comparing major markets including US, EU, Japan and China
    • Risk and Common Mistakes in Import and Export Documentation for Clinical Trials
    • Operational Aspects Of Independent Reviews for Immune-Oncology Clinical Endpoints
    • PAREXEL Academy Introduces New Collaboration to Develop Japan’s Biopharmaceutical Workforce of the Future
    • The Evolution of Randomization and Trial Supply Management Services
    • Exploring ways to enhance evidence generation & communication planning
    • FDA initiatives under 21st Century Cures Act
    • Seamless dataflow with a clinical Metadata Repository
    • PAREXEL Introduces Peyton Howell as Chief Commercial & Strategy Officer
    • Effective Regulatory Strategies for China Market Entry
    • Leveraging Imaging And Wearable Technology For Agile Trial Conduct
    • Increased Internal Collaboration is a Prerequisite for Improved Value Communication
    • Communicating Product Value for Success: Every Word Counts
    • Industry Experts Gather at PAREXEL for 2018 ISPE Investigational Products Community of Practice Symposium
    • Effective Strategies for Successful Global Development
    • Trends in Early Development
    • Understanding regulatory and payer requirements throughout commercialization
    • Interview: Greg Rush, Executive Vice President and Chief Financial Officer
    • Life of a Biosimilar
    • Improving Processes for Temperature Traceability from Packaging to Patient
    • Interview: Jason Martin, PAREXEL Corporate Vice President, Global Data Operations, and Travis May, Datavant co-founder and CEO
    • World Alzheimer’s Day: Reflecting on Progress and a Need for Collaboration Among Patients, Caregivers and the Drug Development Industry to Advance New Treatments
    • Improving Drug Development and Patient Access With the Right People, Processes, and Culture
    • PAREXEL Acknowledges World Cancer Day 2019
    • January Flurry: Our Regulatory experts share their perspective on a busy month at the FDA
    • Unlocking Drug Development Innovation with the Right People, Processes & Culture
  • agile-IRT
    • Agile IRT
    • Reduced Timelines
    • Simpler Processes
    • Expert Services
    • Contact
  • test
    • Graduate | PAREXEL
  • Menu
Home > parexel-insights > January Flurry: Our Regulatory...

January Flurry: Our Regulatory experts share their perspective on a busy month at the FDA

By Corporate Communications
February 1, 2019

Despite the recent US government shutdown, the FDA has been busy this month. PAREXEL’s experts chimed in on key updates from the Agency and their impact on the industry.

Commentary on Commissioner Gottlieb’s statement regarding growth in Cell and Gene therapy IND’s, by Mo Heidaran, PhD., Vice President Technical, PAREXEL Consulting

In a recent statement, FDA Commissioner Gottlieb acknowledged tremendous growth in number of INDs submitted in cell and gene therapy, pointing to 200 new INDs per year and 800 active INDs in this space.

To address this and keeping pace with the number of INDs submitted to the agency, Dr. Gottlieb announced hiring as many as 50 new clinical reviewers, without mentioning any plan for expansion of staff that conduct non-clinical and/or CMC reviews at FDA.

CMC readiness remains one of the major challenges in the expedited development of cell and gene therapy products. While Dr. Gottlieb’s plan is a significant step forward, it is only part of the solution. In view of these extraordinary demands facing the field it behooves the agency to plan for the expansion of not only clinical reviewers but also consider increasing the capacities and capabilities for CMC and non-clinical reviewers.

Not doing so most likely will create a very disruptive imbalance in the review management process creating unintended consequences that could impact safety and robust commercial processing of the products being evaluated in clinical trials. PAREXEL is committed to filling this gap by providing a comprehensive and fully integrated service to our clients streamlining product development lifecycle by avoiding the major pitfalls in early and late stage product development.

FDA Publishes Draft Guidance-Rare Diseases: Common Issues in Drug Development, by Brad Gillespie, Principal Consultant, PAREXEL Consulting

FDA issued a draft guidance document intended to assist sponsors in the development of orphan drugs. This document is largely focused on strategies to facilitate the conduct of more efficient and ultimately more successful development programs for drugs intended to treat or prevent rare diseases.

While the need to fully document the safety and efficacy is the same for orphans as for all drugs, FDA is open-minded in its approach due to the challenges inherent to the development these compounds. In this important document, several approaches are described that are intended to facilitate and expedite the development of orphan drugs.

A full analysis of the guidance is available here. In summary, publication of this guidance provides assurance that FDA is serious about supporting the development of drugs to counter rare diseases. Some of the suggested approaches are novel and may require unique expertise.

Lastly, a central theme of this document is the benefit of maintaining early and frequent communication with the Agency. PAREXEL is acutely aware of the challenges associated with orphan drugs. While the foundation of PAREXEL is broad and deep internal expertise in all phases of orphan drug development, it has also gained extensive Regulatory and Clinical development experience, guiding a variety of orphan drug clients through successful development and regulatory interactions.

FDA Publishes Draft Guidance - Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway January 2019, by Mamata Gokhale, Principal Consultant, PAREXEL Consulting

The accelerated approval is one of several approaches used by the FDA to expedite the development of drugs for serious or life-threatening diseases and conditions upon determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on an intermediate endpoint that can be measured earlier than irreversible morbidity or mortality.

This draft guidance focuses on how accelerated approval is represented in the Indications and Usage section of product labeling (USPI) and offers recommendations to sponsors on language that best conveys different circumstances specific to accelerated approval. 

PAREXEL has internal expertise (industry and ex-FDA) in accelerated drug development and corresponding labeling for drugs and biologics, and we highlighted some specific recommendations of interest for companies seeking accelerated approval:

  • Indication and Usage statement for drugs approved under the accelerated approval framework must acknowledge that the drug was approved based upon accelerated approval and that continued approval for the drug (or indication) may be contingent upon verification and description of clinical benefit in a confirmatory trial or trials.

  • Effect on surrogate endpoint or intermediate clinical endpoint such as response rate that supported the accelerated approval needs to be described in the Indication and Usage statement and should be cross referenced to the Clinical Studies section of the label.

  • A similar presentation should also be used under the Indications and Usage heading in Highlights without a cross-reference to the Clinical Studies.

  • Continuation of accelerated approval is subject to the requirement that confirmatory trials verify the drug’s clinical benefit. Therefore the Indication and Usage statement also needs to state that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

How should labeling be revised after successful verification and description of clinical benefit in post-marketing studies? Read more in our PAREXEL Consulting Blog here.

FDA Accelerates Initiatives to Modernize and Strengthen 510(k) Program, by Sugato De, Vice President – Technical, PAREXEL Consulting

Since its inception over forty-two years ago, FDA’s 510(k) clearance pathway has served as a core pillar of medical device marketing authorizations in the United States. 

Under this pathway, manufacturers of Class II medical devices and in vitro diagnostics have been able to pursue a streamlined path to clearance based on a demonstration of substantial equivalence to a legally marketed predicate device. 

Beginning in earnest with the issuance of FDA’s Medical Device Safety Action Plan in early 2018, FDA has put renewed focus on advancing multiple initiatives to enhance the safety of medical devices and keep pace with the increased complexity of rapidly evolving technologies. 

Last week, FDA issued an announcement of two key developments that signal progress toward its previously reported goal to modernize the 510(k) program. 

First, FDA posted its final guidance entitled “Safety and Performance Based Pathway,” which updates a draft guidance from April 12, 2018.  The guidance introduces a new option for manufacturers to obtain 510(k) clearance by referencing objective performance criteria recognized by FDA to facilitate demonstrations of substantial equivalence. 

Second, FDA is soliciting public comment on steps the Agency can take to further enhance the safety of 510(k) devices.  To learn more about each of these updates, please visit our PAREXEL Consulting blog here.

Evolving standards of care and the proliferation of innovative technologies demand a regulatory environment where new medical devices are held to a higher bar.  Patients deserve access to medical devices that conform to modern safety and performance standards, and regulators should not be expected to operate within a framework that enables the clearance of new medical devices based on comparison to outdated predicates that represent the lowest common denominator of that device type.

FDA’s sentiment and initiative in this area is laudable, and it is a positive sign that the Agency is seeking further input to refine its approach.  PAREXEL Consulting’s experts support companies in developing regulatory strategies, clinical development plans, premarket submissions and compliance programs for medical devices and are actively tracking updates and providing input to FDA’s 510(k) modernization initiative.

Corporate Communications
Ask a Question

Share via

Related Articles

Topic

Cell Therapy

Consulting

Gene Therapy

Rare Diseases

Regulatory and Market Access

Regulatory Submissions

Therapeutic Expertise

Linkedin Updates

View Profile

CAREERS AT PAREXEL®

If you are inspired to make a difference
in the world, we can help you make it possible.

Search job openings worldwide

PAREXEL International Corp.
+1 781 487 9900
195 West Street
Waltham, MA 02451 

  • ABOUT PAREXEL®
  • NEWS & EVENTS
  • VOLUNTEER
  • CONTACT
  • MY PAREXEL PREFERENCE CENTER
  • CLIENT LOGIN
  • LIQUENT®
  • CLINICAL TRIAL INVESTIGATOR
  • SITE MAP
  • TERMS OF SERVICE
  • PRIVACY POLICY
  • EU-U.S. AND SWISS-U.S. PRIVACY SHIELD NOTICE OF CERTIFICATION

Copyright ©2000-2019 PAREXEL International Corporation.